Novel delivery systems can successfully deliver miRNAs to tumor locations without being degraded by RNase in blood and show obvious adverse effects in patients, encapsulating si-lncRNA DLX6-AS1 in lipid nanoparticles to deliver them to tumor sites using the EPR (enhanced permeability and retention) effect on tumor locations (Matsumura et al., 1986). Here, DLX6 is linked to neoplasm.